Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2014

View Archived Issues

Researchers identify selective PIP5K1-alpha inhibitor

Promising phase I results presented for the anti-TNF antibody AVX-470

Neurocrine initiates phase III trial of NBI-98854 in tardive dyskinesia

Cardiotrophin-1 granted FDA orphan designation for use in kidney transplantation

Researchers at Janssen R&D Ireland disclose novel TLR7 agonists

New MetAP 2 inhibitors patented by Sanofi

Ajinomoto divulges new series of SPK 1 inhibitors

Sanofi patents novel cathepsin A inhibitors

Roche divulges new CB2 receptor agonists

TWi Biotechnology's AC-201 receives FDA orphan drug designation

GSK and Sumitomo Dainippon Pharma to end Japanese copromotion of Paxil CR

Phase II data for QAX-576 in fistulizing Crohn's disease

Quadrivalent influenza vaccine well tolerated after intradermal administration

Enanta Pharmaceuticals updates on its HCV protease inhibitor collaboration with AbbVie

AbbVie and Shire agree to terminate proposed merger

Inovio, MedImmune and Penn to develop DNA MAbs for infectious diseases

Pharmacokinetic and safety data presented for Ryanodex

Pivotal study begins of BreathID test for clinically significant portal hypertension

Fujifilm starts production of Avigan in preparation for Ebola virus infection trials

Cannabis Technologies changes name

Cornerstone initiates phase I study of CPI-613 in Hodgkin's lymphoma and NHL

EMA grants orphan drug designation to Epidiolex for Dravet syndrome

Boehringer Ingelheim's nintedanib enters phase III trial in colorectal cancer

Agios initiates phase I/II study of AG-221 in solid tumors

FDA panel recommends approval of Kalydeco for R117H mutation in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...